In the PNET dataset, 3.3% of cases harboured TSC1 or TSC2 mutations conferring sensitivity to the mammalian target of rapamycin (mTOR) inhibitor, everolimus, currently approved for renal angiomyolipomas and giant cell astrocytomas. Here, TSC2 is linked to kidney angiomyolipoma.